阿克拉霉素协同顺铂杀伤卵巢癌细胞中泛素表达

THE ROLE OF UBIQUITIN IN ACLARUBICIN COMBINATION WITH CISPLATIN TO KILL OVARIAN CELLS

为探讨泛素在阿克拉霉素(aclarubicin,ACR)协同顺铂(cisplatin,CDDP)杀伤卵巢癌细胞中的作用,应用ACR及CDDP的药物血浆峰浓度,分别及共同作用SKOV3卵巢癌细胞株24h。采用吖啶橙、嗅乙啶双荧光染色观察细胞活率;克隆培养观察克隆形成率,以及免疫细胞化学方法检测泛素表达。结果可见:细胞活率,ACR组为78.3±3.1;CDDP组为70.1±6.6;ACR和CDDP共用组为50.8±3.2(P<0.05)。克隆培养显示,ACR和CDDP共用组能够显著抑制细胞的生存能力。同时,两药共用组细胞内泛素表达水平明显高于药物单用组。以上结果表明:ACR与CDDP合用能够提高对卵巢癌细胞杀伤效果,泛素-蛋白质降解途径在其中发挥重要作用。

For investigating the role of ubiquitin in aclarubicin(ACR) combination with cisplatin( CD-DP) to kill ovarian cancer cells, the peak serum concentration of ACR and CDDP were used separately, or combined with each other to treat the SKOV3 ovarian cancer cell line for 24 hours. The double fluorescence stain with acridine orange and ethidium bromide was performed to detect the cell vitality. The clone culture method was used to test the cell viability. The immunocytochemstry stain was applied to observe ubiquitin expression of the cells after induced by the drugs. It was observed that the cell vitality was 78. 3±3.1 for the ACR alone, 70.1±6.6 for the CDDP alone, and 50.8±3.2 for the ACR combined with CDDP( P < 0. 05). It was shown that treatment with ACR and CDDP could significantly reduce the cell viability to contrast with only ACR or CDDP used depending on the results of clone culture. It was also noticed that there is a higher u-biquitin expression in the cells by the two drugs used together over the other groups. In conclusion, ACR combined with CDDP can increase the efficiency of killing the ovarian cancer cells, and the ubiquitin-protein degradation system might play an important role in it.